A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/5/2018 |
| Start Date: | May 1, 2017 |
| End Date: | April 2020 |
| Contact: | Jolene Daniel |
| Email: | jolened@med.umich.edu |
| Phone: | 734-615-1901 |
A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections
Administration of concomitant antibiotics (CA) is a known risk factor for treatment failure
in the treatment of CDI, as well as for recurrence of CDI. Recent data suggested that among
patients receiving CA, fidaxomicin is superior vancomycin. While these data are encouraging,
many clinicians remain unclear on how to apply these data to patient care. Additionally,
patients were excluded from the trials presented to the FDA if it was expected that they
would require ≥ 7 days of CA. Therefore, the clinical question still remains of how to apply
these data to the real world patient who requires a long course of CA and develops CDI while
on therapy. We therefore propose an open label, comparative and prospective study of
fidaxomicin 200 mg twice daily vs oral vancomycin 125 mg four times daily for the treatment
of CDI among patients who are receiving a long course of CA.
We hypothesize that fidaxomicin will be superior to vancomycin with respect to clinical cure
for patients with CDI.
in the treatment of CDI, as well as for recurrence of CDI. Recent data suggested that among
patients receiving CA, fidaxomicin is superior vancomycin. While these data are encouraging,
many clinicians remain unclear on how to apply these data to patient care. Additionally,
patients were excluded from the trials presented to the FDA if it was expected that they
would require ≥ 7 days of CA. Therefore, the clinical question still remains of how to apply
these data to the real world patient who requires a long course of CA and develops CDI while
on therapy. We therefore propose an open label, comparative and prospective study of
fidaxomicin 200 mg twice daily vs oral vancomycin 125 mg four times daily for the treatment
of CDI among patients who are receiving a long course of CA.
We hypothesize that fidaxomicin will be superior to vancomycin with respect to clinical cure
for patients with CDI.
Inclusion Criteria:
- Patients 18 years of age or older with >3 unformed stools/24 hours with positive stool
test for C. difficile.
- Patients receiving ≥ 1 high or medium risk antibiotic for treatment of an infection
other than CDI, for an anticipated duration of ≥ 5 days from the time of enrollment.
Exclusion Criteria:
- Patients with severe-complicated disease that would compromise oral therapy
(hypotenstion or shock, ileus or bowel obstruction, megacolon).
- Patients with an allergy to oral vancomycin or fidaxomicin.
- Patients anticipated to receive metronidazole after enrollment.
- Patients who already received oral vancomycin or metronidazole (either oral or
intravenous) for > 24 hours within the preceding 72 hours at the time of enrollment.
- Patients anticipated to receive adjunctive C. difficile therapy (rifaxamin,
nitazoxanide, tigecycline) after enrollment.
We found this trial at
1
site
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
